BAM (8-22) Clinical Trials

Size	Price	Qty
5mg	USD 990

Clinical Trials

BAM (8-22) and related therapeutic research regimens have been evaluated across multiple clinical trials. These studies investigate diverse conditions, including bile acid malabsorption, irritable bowel syndrome with diarrhea, chronic diarrhea, COVID-19, multiple myeloma, and itch. The clinical landscape features Phase 2 and Phase 4 trials sponsored by academic entities such as the University of Chicago and the University of Virginia, as well as industry sponsors like Allergan and Eli Lilly and Company. Most of these trials have reached completed recruitment status, as demonstrated by studies such as NCT05130047 focusing on chronic diarrhea and NCT00317811 evaluating plasma cell neoplasms.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05610111	COMPLETED	Type 1 Diabetes	Sue Brown	2023-01-18
NCT05130047	COMPLETED	Chronic Diarrhea; Irritable Bowel Syndrome With Diarrhea; Bile Acid Malabsorption; Bile Acid Diarrhea; Bile Acid Malabsorption Syndrome Type II; Functional Diarrhea	Michael Camilleri, MD	2021-12-01	PHASE2
NCT04784637	COMPLETED	Type 1 Diabetes Mellitus	University of Virginia	2021-07-23
NCT04634409	COMPLETED	COVID-19	Eli Lilly and Company	2020-10-29	PHASE2
NCT04588532	COMPLETED	Itch	Aalborg University	2020-10-01
NCT04197440	UNKNOWN	Itch	Aalborg University	2020-01-15
NCT03441581	COMPLETED	Irritable Bowel Syndrome With Diarrhea	Allergan	2018-02-23	PHASE4
NCT03367858	COMPLETED	Alcohol Use, Unspecified	University of Rhode Island	2017-01
NCT01927523	UNKNOWN	Youth Violence; Crime; Educational Achievement	University of Chicago	2013-08
NCT02078856	COMPLETED	Bile Acid Malabsorption	Albireo	2014-03	PHASE2
NCT00317811	COMPLETED	Multiple Myeloma and Plasma Cell Neoplasm	Oncotherapeutics	2005-11	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-07)

Check the BAM (8-22) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

BAM (8-22) selectively binds to and activates Mas-related G-protein-coupled receptors, specifically hMrgprX1 and MrgprC11, triggering downstream G-protein signaling cascades within sensory neurons. This cellular stimulation induces neuronal excitation and pruritic signal transduction, directly linking its mechanism to clinical trial research targeting itch mechanisms and sensory neuropathies.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).